Please use this identifier to cite or link to this item:
https://hdl.handle.net/11499/7329
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Pay, S. | - |
dc.contributor.author | Öztürk, M.A. | - |
dc.contributor.author | Can, G. | - |
dc.contributor.author | Cefle, A. | - |
dc.contributor.author | Çobankara, Veli. | - |
dc.contributor.author | Erer, B. | - |
dc.contributor.author | Gö?üş, F. | - |
dc.date.accessioned | 2019-08-16T12:19:58Z | |
dc.date.available | 2019-08-16T12:19:58Z | |
dc.date.issued | 2008 | - |
dc.identifier.issn | 1462-0324 | - |
dc.identifier.uri | https://hdl.handle.net/11499/7329 | - |
dc.identifier.uri | https://doi.org/10.1093/rheumatology/ken026 | - |
dc.description.abstract | Abstract Not Available | en_US |
dc.language.iso | en | en_US |
dc.publisher | Oxford University Press | en_US |
dc.relation.ispartof | Rheumatology | en_US |
dc.rights | info:eu-repo/semantics/openAccess | en_US |
dc.subject | adalimumab | en_US |
dc.subject | etanercept | en_US |
dc.subject | infliximab | en_US |
dc.subject | antirheumatic agent | en_US |
dc.subject | tumor necrosis factor alpha | en_US |
dc.subject | adult | en_US |
dc.subject | ankylosing spondylitis | en_US |
dc.subject | cancer risk | en_US |
dc.subject | drug substitution | en_US |
dc.subject | drug withdrawal | en_US |
dc.subject | female | en_US |
dc.subject | health survey | en_US |
dc.subject | hematologic malignancy | en_US |
dc.subject | human | en_US |
dc.subject | juvenile rheumatoid arthritis | en_US |
dc.subject | letter | en_US |
dc.subject | major clinical study | en_US |
dc.subject | male | en_US |
dc.subject | priority journal | en_US |
dc.subject | psoriatic arthritis | en_US |
dc.subject | rheumatoid arthritis | en_US |
dc.subject | risk assessment | en_US |
dc.subject | risk factor | en_US |
dc.subject | solid tumor | en_US |
dc.subject | Turkey (republic) | en_US |
dc.subject | adolescent | en_US |
dc.subject | arthritis | en_US |
dc.subject | chemically induced disorder | en_US |
dc.subject | clinical trial | en_US |
dc.subject | drug antagonism | en_US |
dc.subject | middle aged | en_US |
dc.subject | multicenter study | en_US |
dc.subject | neoplasm | en_US |
dc.subject | Adolescent | en_US |
dc.subject | Adult | en_US |
dc.subject | Antirheumatic Agents | en_US |
dc.subject | Arthritis | en_US |
dc.subject | Female | en_US |
dc.subject | Humans | en_US |
dc.subject | Male | en_US |
dc.subject | Middle Aged | en_US |
dc.subject | Neoplasms | en_US |
dc.subject | Risk Assessment | en_US |
dc.subject | Tumor Necrosis Factor-alpha | en_US |
dc.title | Risk of cancer in Turkish patients after treatment with TNF antagonists | en_US |
dc.type | Letter | en_US |
dc.identifier.volume | 47 | en_US |
dc.identifier.issue | 4 | en_US |
dc.identifier.startpage | 548 | |
dc.identifier.startpage | 548 | en_US |
dc.identifier.endpage | 549 | en_US |
dc.authorid | 0000000312647971 | - |
dc.identifier.doi | 10.1093/rheumatology/ken026 | - |
dc.relation.publicationcategory | Diğer | en_US |
dc.identifier.scopus | 2-s2.0-43049166010 | en_US |
dc.identifier.scopusquality | Q1 | - |
dc.owner | Pamukkale University | - |
item.languageiso639-1 | en | - |
item.fulltext | With Fulltext | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.cerifentitytype | Publications | - |
item.openairetype | Letter | - |
item.grantfulltext | open | - |
crisitem.author.dept | 14.02. Internal Medicine | - |
Appears in Collections: | Scopus İndeksli Yayınlar Koleksiyonu / Scopus Indexed Publications Collection Tıp Fakültesi Koleksiyonu |
Files in This Item:
File | Size | Format | |
---|---|---|---|
ken026.pdf | 128.52 kB | Adobe PDF | View/Open |
CORE Recommender
SCOPUSTM
Citations
8
checked on Nov 16, 2024
Page view(s)
24
checked on Aug 24, 2024
Download(s)
28
checked on Aug 24, 2024
Google ScholarTM
Check
Altmetric
Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.